VEGF and angiopoietins in diabetic glomerulopathy: How far for a new treatment?

Metabolism: Clinical and Experimental

Volumn 61, Issue 12, 2012, Pages 1666-1673

  Dei Cas, Alessandra ^a   Gnudi, Luigi ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Angiopoietins; Diabetic nephropathy; Therapy; Vascular endothelial growth factor

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; BEVACIZUMAB; ENDOSTATIN; RANIBIZUMAB; TUMSTATIN; VASCULOTROPIN; VASCULOTROPIN A;

DIABETIC NEPHROPATHY; DRUG TARGETING; GLOMERULAR FILTRATION BARRIER; HUMAN; KIDNEY FUNCTION; MEDICAL LITERATURE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ALBUMINURIA; ANGIOGENESIS INHIBITORS; ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANGIOPOIETINS; ANIMALS; DIABETIC NEPHROPATHIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY GLOMERULUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84869492634     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2012.04.004     Document Type: Review

References (77)

1. E. Ritz, I. Rychlik, and F. Locatelli End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions Am J Kidney Dis 34 1999 795 808 (Pubitemid 29521694)
2. A. Schieppati, and G. Remuzzi Chronic renal diseases as a public health problem: epidemiology, social, and economic implications Kidney Int Suppl 98 2005 S7 S10
3. G. Bruno, P. Cavallo-Perin, and G. Bargero Prevalence and risk factors for micro- and macroalbuminuria in an Italian population-based cohort of NIDDM subjects Diabetes Care 19 1996 43 47
4. J.P. New, R.J. Middleton, and B. Klebe Assessing the prevalence, monitoring and management of chronic kidney disease in patients with diabetes compared with those without diabetes in general practice Diabet Med 24 2007 364 369 (Pubitemid 46452394)
5. U S Renal Data System USRDS 2010 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States 2010 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD
6. A.I. Adler, R.J. Stevens, S.E. Manley, R.W. Bilous, C.A. Cull, and R.R. Holman Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64) Kidney Int 63 2003 225 232 (Pubitemid 35463925)
7. J. Karalliedde, and G. Viberti Proteinuria in diabetes: bystander or pathway to cardiorenal disease? J Am Soc Nephrol 21 2010 2020 2027
8. G. Wolf, and F.N. Ziyadeh Cellular and molecular mechanisms of proteinuria in diabetic nephropathy Nephron Physiol 106 2007 26 31
9. K. Asanuma, and P. Mundel The role of podocytes in glomerular pathobiology Clin Exp Nephrol 7 2003 255 259 (Pubitemid 38031285)
10. H. Putaala, R. Soininen, and P. Kilpelainen The murine nephrin gene is specifically expressed in kidney, brain and pancreas: inactivation of the gene leads to massive proteinuria and neonatal death Hum Mol Genet 10 2001 1 8 (Pubitemid 32051561)
11. N. Boute, O. Gribouval, and S. Roselli NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome Nat Genet 24 2000 349 354 (Pubitemid 30187431)
12. S. Reitsma, D.W. Slaaf, and H. Vink The endothelial glycocalyx: composition, functions, and visualization Pflugers Arch 454 2007 345 349
13. S. Weinbaum, J.M. Tarbell, and E.R. Damiano The structure and function of the endothelial glycocalyx layer Annu Rev Biomed Eng 9 2007 121 167 (Pubitemid 350246654)
14. B. Haraldsson, J. Nystrom, and W.M. Deen Properties of the glomerular barrier and mechanisms of proteinuria Physiol Rev 88 2008 451 487 (Pubitemid 351522745)
15. S.C. Satchell, and J.E. Tooke What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia 51 2008 714 725
16. M. Ohlson, J. Sörensson, and B. Haraldsson A gel-membrane model of glomerular charge and size selectivity in series Am J Physiol Renal Physiol 280 2001 F396 F405
17. W.M. Deen, M.J. Lazzara, and B.D. Myers Structural determinants of glomerular permeability Am J Physiol Renal Physiol 281 2001 F579 F596
18. L. Gnudi, S.M. Thomas, and G. Viberti Mechanical forces in diabetic kidney disease: a trigger for impaired glucose metabolism J Am Soc Nephrol 18 2007 2226 2232 (Pubitemid 47203836)
19. J.M. Forbes, K. Fukami, and M.E. Cooper Diabetic nephropathy: where hemodynamics meets metabolism Exp Clin Endocrinol Diabetes 115 2007 69 84 (Pubitemid 46408113)
20. B.F. Schrijvers, A.S. De Vriese, and A. Flyvbjerg From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines Endocr Rev 25 2004 971 1010 (Pubitemid 39657775)
21. R.C. Stanton, and G.L. King A complex interplay of factors causes diabetic nephropathy Metabolism 60 2011 591 593
22. I.H. de Boer, W. Sun, and P.A. Cleary Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes N Engl J Med 365 2011 2366 2376
23. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group BMJ 317 1998 703 713
24. H. Takahashi, and M. Shibuya The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions Clin Sci 109 2005 227 241 (Pubitemid 41337127)
25. H.J. Baelde, M. Eikmans, and D.W. Lappin Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss Kidney Int 71 2007 637 645 (Pubitemid 46494557)
26. N. Ferrara, H.P. Gerber, and J. LeCouter The biology of VEGF and its receptors Nat Med 9 2003 669 676 (Pubitemid 36749215)
27. C.H. Ku, and K.E. White Dei Cas A, et al. Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice Diabetes 57 2008 2824 2833
28. D. Veron, K.J. Reidy, and C. Bertuccio Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease Kidney Int 77 2010 989 999
29. K. Sison, V. Eremina, and H. Baelde Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling J Am Soc Nephrol 21 2010 1691 1701
30. B. Robert, X. Zhao, and D.R. Abrahamson Coexpression of neuropilin-1, Flk1, and VEGF(164) in developing and mature mouse kidney glomeruli Am J Physiol Renal Physiol 279 2000 F275 F282
31. R.L. Kendall, and K.A. Thomas Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor Proc Natl Acad Sci U S A 90 1993 10705 10709 (Pubitemid 23347111)
32. R.L. Kendall, G. Wang, and K.A. Thomas Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR Biochem Biophys Res Commun 226 1996 324 328 (Pubitemid 26331903)
33. S.J. Harper, and D.O. Bates VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 8 2008 880 887
34. H.S. Bevan, N.M. van den Akker, and Y. Qiu The alternatively spliced anti-angiogenic family of VEGF isoforms VEGFxxxb in human kidney development Nephron Physiol 110 2008 p57 p67
35. H. Sugimoto, Y. Hamano, and D. Charytan Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria J Biol Chem 278 2003 12605 12608 (Pubitemid 36800018)
36. B.C. Young, R.J. Levine, and S.A. Karumanchi Pathogenesis of preeclampsia Annu Rev Pathol 5 2010 173 192
37. V. Eremina, H.J. Baelde, and S.E. Quaggin Role of the VEGF - a signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier Nephron Physiol 106 2007 32 37
38. V. Eremina, M. Sood, and J. Haigh Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases J Clin Invest 111 2003 707 716 (Pubitemid 36278589)
39. V. Eremina, J.A. Jefferson, and J. Kowalewska VEGF inhibition and renal thrombotic microangiopathy N Engl J Med 358 2008 1129 1136 (Pubitemid 351398487)
40. R.R. Foster, R. Hole, and K. Anderson Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes Am J Physiol Renal Physiol 284 2003 F1263 F1273
41. C. Bertuccio, D. Veron, and P.K. Aggarwal Vascular endothelial growth factor receptor 2 direct interaction with nephrin links VEGF-A signals to actin in kidney podocytes J Biol Chem 286 2011 39933 39944
42. S.C. Satchell, K.L. Anderson, and P.W. Mathieson Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties J Am Soc Nephrol 15 2004 566 574 (Pubitemid 38294786)
43. A.S. Woolf, L. Gnudi, and D.A. Long Roles of angiopoietins in kidney development and disease J Am Soc Nephrol 20 2009 239 244
44. P.C. Maisonpierre, C. Suri, and P.F. Jones Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis Science 277 1997 55 60 (Pubitemid 27450643)
45. S.C. Satchell, S.J. Harper, and J.E. Tooke Human podocytes express angiopoietin 1, a potential regulator of glomerular vascular endothelial growth factor J Am Soc Nephrol 13 2002 544 550 (Pubitemid 34106299)
46. L. Eklund, and B.R. Olsen Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling Exp Cell Res 312 2006 630 641 (Pubitemid 43290339)
47. M. Jeansson, A. Gawlik, and G. Anderson Angiopoietin-1 is essential in mouse vasculature during development and in response to injury J Clin Invest 121 2011 2278 2289
48. A.H. Salmon, C.R. Neal, and L.M. Sage Angiopoietin-1 alters microvascular permeability coefficients in vivo via modification of endothelial glycocalyx Cardiovasc Res 83 2009 24 33
49. A. Pozzi, G. Jarad, and G.W. Moeckel Beta1 integrin expression by podocytes is required to maintain glomerular structural integrity Dev Biol 316 2008 288 301
50. D. Hanahan Signaling vascular morphogenesis and maintenance Science 277 1997 48 50 (Pubitemid 27450640)
51. B. Davis Dei Cas A, Long DA, et al. Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia J Am Soc Nephrol 18 2007 2320 2329 (Pubitemid 47203848)
52. W. Goettsch, C. Gryczka, and T. Korff Flow-dependent regulation of angiopoietin-2 J Cell Physiol 214 2008 491 503 (Pubitemid 350309006)
53. C.M. Findley, M.J. Cudmore, and A. Ahmed VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling Arterioscler Thromb Vasc Biol 27 2007 2619 2626 (Pubitemid 350158914)
54. H. Singh, C.S. Milner, and M.M. Aguilar Hernandez Vascular endothelial growth factor activates the Tie family of receptor tyrosine kinases Cell Signal 21 2009 1346 1350
55. J. Gavard, V. Patel, and J.S. Gutkind Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia Dev Cell 14 2008 25 36
56. B. Rizkalla, J.M. Forbes, and Z. Cao Temporal renal expression of angiogenic growth factors and their receptors in experimental diabetes: role of the renin-angiotensin system J Hypertens 23 2005 153 164 (Pubitemid 40128994)
57. F.C. Sasso, O. Carbonara, and Persico Increased vascular endothelial growth factor mRNA expression in the heart of streptozotocin-induced diabetic rats Metabolism 52 2003 675 678 (Pubitemid 36903150)
58. M.E. Cooper, D. Vranes, and S. Youssef Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes Diabetes 48 1999 2229 2239 (Pubitemid 29521855)
59. K. Tsuchida, Z. Makita, and S. Yamagishi Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195 Diabetologia 42 1999 579 588 (Pubitemid 29196009)
60. N.H. Kim, H.H. Jung, and D.R. Cha Expression of vascular endothelial growth factor in response to high glucose in rat mesangial cells J Endocrinol 165 2000 617 624 (Pubitemid 30407689)
61. D. Veron, C.A. Bertuccio, and A. Marlier Podocyte vascular endothelial growth factor (Vegf164) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes Diabetologia 54 2011 1227 1241
62. A.S. De Vriese, R.G. Tilton, and M. Elger Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes J Am Soc Nephrol 12 2001 993 1000 (Pubitemid 32378340)
63. A. Flyvbjerg, F. Dagnaes-Hansen, and A.S. De Vriese Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody Diabetes 51 2002 3090 3094
64. S.H. Sung, F.N. Ziyadeh, and A. Wang Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice J Am Soc Nephrol 17 2006 3093 3104 (Pubitemid 44707769)
65. P. Hovind, L. Tarnow, and P.B. Oestergaard Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy Kidney Int Suppl 75 2000 S56 S61
66. H.S. Lim, G.Y. Lip, and A.D. Blann Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis Atherosclerosis 180 2005 113 118
67. M.T. Lindenmeyer, M. Kretzler, and A. Boucherot Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy J Am Soc Nephrol 18 2007 1765 1776 (Pubitemid 46870313)
68. Y. Yamamoto, Y. Maeshima, and H. Kitayama Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy Diabetes 53 2004 1831 1840 (Pubitemid 38857042)
69. H. Sun, J.M. Zheng, and S. Chen Enhanced expression of ANGPTL2 in the microvascular lesions of diabetic glomerulopathy Nephron Exp Nephrol 105 2007 e117 e123
70. X. Gao, H. Xu, and H. Liu Angiopoietin-like protein 3 regulates the motility and permeability of podocytes by altering nephrin expression in vitro Biochem Biophys Res Commun 399 2010 31 36
71. L.C. Clement, C. Avila-Casado, and C. Macé Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome Nat Med 17 2011 117 122
72. G. Pellé, N. Shweke, and J.P. Duong Van Huyen Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors Am J Kidney Dis 57 2011 756 759
73. J. Karalliedde, and L. Gnudi Endothelial factors and diabetic nephropathy Diabetes Care 34 2011 S291 S296
74. A. Advani, D.J. Kelly, and S.L. Advani Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions Proc Natl Acad Sci U S A 104 2007 14448 14453 (Pubitemid 350003281)
75. S. Lee, W. Kim, and S.O. Moon Renoprotective effect of COMP-angiopoietin-1 in db/db mice with type 2 diabetes Nephrol Dial Transplant 22 2007 396 408 (Pubitemid 46189882)
76. T. Nakagawa, T. Kosugi, and M. Haneda Abnormal angiogenesis in diabetic nephropathy. Diabetes 58 2009 1471 1478
77. K. Ichinose, Y. Maeshima, and Y. Yamamoto Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model Diabetes 54 2005 2891 2903 (Pubitemid 41401084)